# Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

> **NCT01210495** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 224 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Axitinib (AG-013736)
- **OTHER:** Best Supportive Care
- **DRUG:** Placebo
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT01210495
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-06
- **Primary completion:** 2014-03-03
- **Final completion:** 2016-12-20
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210495, "Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01210495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*